arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

TANDEM DIABETES CARE INC

TNDM
$22.38 ▲ +4.45 (+24.86%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
15 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
13
Health
Poor
Bearish
auto_awesome

Analytical Summary

TANDEM DIABETES CARE INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.5B
Dividend Yield
Revenue Growth 7.9%
Op. Margin -18.5%
ROIC -41.1%
FCF / Share $-0.44
Trailing P/E
Price / Book 9.9x
FCF Yield
Debt / Equity 2.00
info Valuation on last close. End-of-day price, Aug 7, 2026.

15-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.01B
↑ +7.9%
Net Income Profit after all expenses
$-204.71M
↓ -113.2%
Operating Margin Operating profit as % of sales
-18.5%
↓ -75.0% 11th
FCF / Share Free cash flow per share
$-0.44
↓ -677.9%
Long-Term Debt Long-term obligations
$310.04M
↑ +0.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
14
Returns
6
Financial Health
16
Cash Quality
27

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 55 quarters